Idorsia Pharmaceuticals Ltd Revenue and Competitors
Estimated Revenue & Valuation
- Idorsia Pharmaceuticals Ltd's estimated annual revenue is currently $418.8M per year.
- Idorsia Pharmaceuticals Ltd's estimated revenue per employee is $182,000
Employee Data
- Idorsia Pharmaceuticals Ltd has 2301 Employees.
Idorsia Pharmaceuticals Ltd's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Executive Associate to the CEO | Reveal Email/Phone |
2 | Chief Patent Counsel | Reveal Email/Phone |
3 | Chief Technical Operations Officer (CTOO) | Reveal Email/Phone |
4 | VP, Chief Information Office | Reveal Email/Phone |
5 | Chief Commercial Officer | Reveal Email/Phone |
6 | Sn VP, Head Clinical Science | Reveal Email/Phone |
7 | Head Pathology | Reveal Email/Phone |
8 | Head Medicinal Chemistry | Reveal Email/Phone |
9 | Head Pharmaceutical Development and Commercial Supplies , Sr. VP | Reveal Email/Phone |
10 | Head Access and Policy | Reveal Email/Phone |
Idorsia Pharmaceuticals Ltd Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.8M | 27 | -4% | $15.7M | N/A |
#2 | $25.5M | 178 | -3% | N/A | N/A |
#3 | $1.4M | 22 | -50% | $21.2M | N/A |
#4 | $56.6M | 348 | 19% | $6M | N/A |
#5 | $6.3M | 56 | -21% | $216.8M | N/A |
#6 | $0M | 2 | 0% | $33.3M | N/A |
#7 | $33.3M | 233 | 0% | N/A | N/A |
#8 | $32.4M | 232 | -26% | $64.6M | N/A |
#9 | $30M | 215 | -22% | $46.8M | N/A |
#10 | $261.6M | 1407 | 15% | $75M | N/A |
What Is Idorsia Pharmaceuticals Ltd?
N/A
Total Funding
2301
Number of Employees
$418.8M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Idorsia Pharmaceuticals Ltd News
2022-04-19 - Myocardial Infarction (MI) Therapeutics Market to 2030 Insights ...
... Pfizer Inc, CeleCor Therapeutics, Idorsia Pharmaceuticals Ltd. ... there are various specific antidotes of these pharmaceutical drugs...
2022-04-19 - Investegate |Idorsia Pharmaceuticals Ltd Announcements | Idorsia ...
Idorsia Ltd (SIX: IDIA) today announced its financial results for the ... two products in two of the world's largest pharmaceutical markets.
2022-04-13 - PIVLAZ (clazosentan) Idorsia's first commercial product now ...
Idorsia Ltd (SIX: IDIA) and Idorsia Pharmaceuticals Japan today announced that PIVLAZ (clazosentan) is now available to physicians in Japan...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $869.8M | 2301 | 21% | N/A |
#2 | $300M | 2305 | -10% | N/A |
#3 | $678.6M | 2308 | 1% | N/A |
#4 | $663.3M | 2311 | -5% | N/A |
#5 | $582.6M | 2312 | 1% | N/A |